Fidelity National Information Services Inc. Stock Falls Monday, Underperforms Market

Sierra Oncology Inc

Change company Symbol lookup

Select an option...

SRRA Sierra Oncology Inc

ICPT Intercept Pharmaceuticals Inc

MO Altria Group Inc

AI C3.ai Inc

INUV Inuvo Inc

PZZA Papa John's International Inc

REVHU Revolution Healthcare Acquisition Corp

DORM Dorman Products Inc

MDT Medtronic PLC

BA Boeing Co

Health Care : Biotechnology | Small Cap Value
Based in Canada

Company profile

Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).

Fidelity National Information Services Inc. Stock Falls Monday, Underperforms Market

4:54 pm ET January 10, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Fidelity National Information Services Inc. (FIS) slipped 1.08% to $116.37 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.14% to 4,670.29 and Dow Jones Industrial Average falling 0.45% to 36,068.87. The stock's fall snapped a five-day winning streak. Fidelity National Information Services Inc. closed $39.59 short of its 52-week high ($155.96), which the company achieved on April 29th.

The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Visa Inc. Cl A (V) fell 2.30% to $211.97, Mastercard Inc. (MA) fell 1.55% to $363.91, and Fiserv Inc. (FISV) fell 0.99% to $107.75. Trading volume (5.8 M) eclipsed its 50-day average volume of 4.4 M.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 10, 2022.

-MarketWatch Automation

(END) Dow Jones Newswires

January 10, 2022 16:54 ET (21:54 GMT)